Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Fluo Labs Unveils a Revolutionary New Device Poised to Transform How People Manage Hay Fever Symptoms

Affordable and Drug-Free, Flō Provides Rapid Relief With No Known Side Effects.


News provided by

Fluo Labs

Jan 12, 2021, 08:00 ET

Share this article

Share toX

Share this article

Share toX

New device from Fluo Labs promises to dramatically improve the way people manage hay fever.
New device from Fluo Labs promises to dramatically improve the way people manage hay fever.

LAS VEGAS, Jan. 12, 2021 /PRNewswire-PRWeb/ -- Fluo Labs, a medical device company on a mission to improve the quality of life for millions of allergy sufferers, today unveiled Flō, a breakthrough device that promises to dramatically improve the way people manage Allergic Rhinitis (AR) -- more commonly known as hay fever. With a successful clinical trial under its belt, the working prototype treats AR by using light therapy to inhibit the release of histamines and reduce inflammation - effectively acting as a natural antihistamine. The new device is affordable, easy-to-use, drug-free and provides rapid relief with no known side effects and no prescription needed. Created by a team of experts in the fields of light therapeutics, antihistamines, and nasal steroids, the technology is the result of more than 15 years of cutting-edge research, preclinical and clinical development. Fluo Labs has two additional clinical trials planned and is pursuing FDA approval for the use of the device as an OTC device. Flō is expected to be available for purchase in late 2021.

Allergic Rhinitis (AR) causes a wide variety of misery-inducing symptoms such as sneezing, congestion, runny nose, itchy and watery eyes, headaches and fatigue. To add insult to injury, climate change has lengthened the average allergy season, prolonging and intensifying people's suffering.To treat AR symptoms, many people turn to over-the-counter allergy medications and immunotherapy. While these medications work for many people, they may not be the right solution for everyone and carry the added risk of side effects that could be even more problematic than the original hay fever symptoms.

Fluo Labs unveils new device that provides a drug-free way for people manage hay fever.

Post this

"For consumers who are seeking non-drug solutions, there has been no single natural remedy that can do the job of providing efficient symptom relief in a convenient treatment - until now," said Jan Enemaerke, Fluo Labs' Chief Technology Officer and Co-Founder. "Our device will provide welcome relief to the millions of allergy sufferers around the world, especially for those who don't want to or cannot take medication due to contraindications, pregnancy, heart or thyroid conditions and job restrictions."

Flō treats AR through a light therapy known as photobiomodulation. Used by the medical community for pain relief, inflammation reduction, wound healing and tissue regeneration, photobiomodulation operates a beneficial photochemical effect where light engenders a chemical change as it is absorbed by the body's tissue. In other words, the transformation of light to energy triggers a complex set of physical and chemical reactions that can enhance the cells' performance and health responses.

At under $100, the allergy device is a one-time purchase that will last through multiple allergy seasons, making each treatment less expensive than antihistamines or corticosteroids, especially for moderate and severe sufferers who must consume drugs for extended periods of time. is also one of four finalists of the P&G Ventures CES Innovation Challenge.

How It Works
Flō uses a patented light delivery system of safe light that defends the nose against allergens. Fluo Labs' scientists have identified the optimal therapeutic window - that precise balance of wavelength, dosage, power and pulse structure - that can effectively inhibit the release of histamines while also working to reduce inflammation. This means that the therapeutic light emitted by the device works as a natural antihistamine that has no known side effects.

The allergy treatment takes less than 20 seconds. To use, simply:

  • Hold the device up to your nostril
  • Click the button for 10 seconds of light therapy
  • Repeat in the other nostril
  • Repeat steps 1-3 as needed once or twice a day.

Clinical Studies
Fluo Labs conducted an IRB-sanctioned pilot study to evaluate the effectiveness and safety of the first version of the device in reducing symptoms of ragweed allergic rhinitis. The study yielded a 31% improvement in the Total Nasal Symptom Score (TNSS) over baseline. The TNSS score measures congestion, itching, runny nose and sneezing and compares results over a 14-day period to a baseline. TNSS is the gold standard in allergy tests. The results from the Fluo Labs pilot study were significant and superior to what is generally achieved with antihistamines, with the added benefit of no known side effects. Fluo Labs currently has two clinical studies planned in 2021.

Consumers who are interested in purchasing the medical device can sign up for the waitlist at: https://www.fluolabs.care/join-the-waitlist.

About Fluo Labs
Fluo Labs is a medical device company on a mission to improve the quality of life for millions of allergy sufferers. Fluo Labs' founders have decades of industry experience in the development of cutting-edge, light-based medical devices and extensive experience in multiple pharma and biotech therapeutic areas including virology, rhinitis drug therapies and light therapeutics. It's first product, allows people to treat the symptoms of allergic rhinitis through a natural, clean, over-the-counter remedy. To learn more, visit: https://www.fluolabs.care/.

Media Contact

Linden Kohtz Garcia, CommStrat, (512) 964-3784, [email protected]

SOURCE Fluo Labs

Related Links

http://www.fluolabs.care

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.